Effects of the Lysine Methyltransferase Inhibitor AZ505 on Bone Metabolism
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Protein methylation has important role in regulating diverse cellular responses, including differentiation, by affecting protein activity, stability, and interactions. AZ505 is an inhibitor of the SET and MYND domain-containing protein 2 lysine methylase. In this study, we investigated the effect of AZ505 on osteoblast and osteoclast differentiation in vitro and evaluated the effect of AZ505 in vivo on the long bones in mice. Methods: Osteoblast differentiation was assessed by alkaline phosphatase (ALP) and Alizarin red staining after culturing calvarial preosteoblasts in an osteogenic medium. Osteoclast differentiation was analyzed by tartrate-resistant acid phosphatase (TRAP) staining in bone marrow-derived macrophages cultured with macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL). For in vivo experiments, mice were intraperitoneally injected with AZ505 and femurs were examined by micro-computed tomography. Results: AZ505 increased ALP and Alizarin red staining in cultured osteoblasts and the expression of osteoblast marker genes, including Runx2 and osteocalcin. AZ505 resulted in decreased TRAP-staining of osteoclasts and expression of c-Fos and nuclear factor of activated T cells transcription factors and osteoclast marker genes, including cathepsin K and dendritic cell-specific transmembrane protein. Unexpectedly, in vivo administration of AZ505 markedly decreased the trabecular bone mass of femurs. In support of this catabolic result, AZ505 strongly upregulated RANKL expression in osteoblasts. Conclusions: The results indicate that AZ505 has a catabolic effect on bone metabolism in vivo despite its anabolic effect in bone cell cultures. The findings indicate that cell culture data should be extrapolated cautiously to in vivo outcomes for studying bone metabolism.
Abstract
Background: Protein methylation has important role in regulating diverse cellular responses, including differentiation, by affecting protein activity, stability, and interactions. AZ505 is an inhibitor of the SET and MYND domain-containing protein 2 lysine methylase. In this study, we investigated the effect of AZ505 on osteoblast and osteoclast differentiation in vitro and evaluated the effect of AZ505 in vivo on the long bones in mice. Methods: Osteoblast differentiation was assessed by alkaline phosphatase (ALP) and Alizarin red staining after culturing calvarial preosteoblasts in an osteogenic medium. Osteoclast differentiation was analyzed by tartrate-resistant acid phosphatase (TRAP) staining in bone marrow-derived macrophages cultured with macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL). For in vivo experiments, mice were intraperitoneally injected with AZ505 and femurs were examined by micro-computed tomography. Results: AZ505 increased ALP and Alizarin red staining in cultured osteoblasts and the expression of osteoblast marker genes, including Runx2 and osteocalcin. AZ505 resulted in decreased TRAP-staining of osteoclasts and expression of c-Fos and nuclear factor of activated T cells transcription factors and osteoclast marker genes, including cathepsin K and dendritic cell-specific transmembrane protein. Unexpectedly, in vivo administration of AZ505 markedly decreased the trabecular bone mass of femurs. In support of this catabolic result, AZ505 strongly upregulated RANKL expression in osteoblasts. Conclusions: The results indicate that AZ505 has a catabolic effect on bone metabolism in vivo despite its anabolic effect in bone cell cultures. The findings indicate that cell culture data should be extrapolated cautiously to in vivo outcomes for studying bone metabolism.
참고문헌 (34)
- Matlock A. Jeffries, "The Development of Epigenetics in the Study of Disease Pathogenesis", Advances in Experimental Medicine and Biology, 1253, pp.57~94 (2020), Springer Singapore[DOI]
- 조영단, "Trans-differentiation via Epigenetics: A New Paradigm in the Bone Regeneration", 대한골대사학회지, 25(1), pp.9~13 (2018), 대한골대사학회[DOI]
- Xin Yi, "Histone methyltransferase SMYD2: ubiquitous regulator of disease", Clinical Epigenetics, 11(1), pp.112~ (2019), Springer Science and Business Media LLC[DOI]
- Naveen Parmar, "Leishmania donovani Subverts Host Immune Response by Epigenetic Reprogramming of Macrophage M(Lipopolysaccharides + IFN-γ)", M(IL-10) Polarization, 2020, pp.204(10), 2762~2778[DOI]
- Ryuji Hamamoto, "Critical roles of non-histone protein lysine methylation in human tumorigenesis", Nature Reviews Cancer, 15(2), pp.110~124 (2015), Springer Science and Business Media LLC[DOI]
- Jing Huang, "Repression of p53 activity by Smyd2-mediated methylation", Nature, 444(7119), pp.629~632 (2006), Springer Science and Business Media LLC[DOI]
- Scoumanne A, "Protein methylation : a new mechanism of p53 tumor suppressor regulation", Histol Histopathol, 23, pp.1143~1149 (2008)[DOI]
- Hyun-Soo Cho, "RB1 Methylation by SMYD2 Enhances Cell Cycle Progression through an Increase of RB1 Phosphorylation", Neoplasia, 14(6), pp.476~486 (2012), Elsevier BV[DOI]
- Xi Zhang, "Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation", Proceedings of the National Academy of Sciences, 110(43), pp.17284~17289 (2013), Proceedings of the National Academy of Sciences[DOI]
- Yuanyuan Jiang, "Structural Insights into Estrogen Receptor α Methylation by Histone Methyltransferase SMYD2, a Cellular Event Implicated in Estrogen Signaling Regulation", Journal of Molecular Biology, 426(20), pp.3413~3425 (2014), Elsevier BV[DOI]
- Andrew D. Ferguson, "Structural basis of substrate methylation and inhibition of SMYD2", Structure, 19(9), pp.1262~1273 (2011), Elsevier BV[DOI]
- Edoardo Fabini, "Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends", Future Medicinal Chemistry, 11(8), pp.901~921 (2019), Future Science Ltd[DOI]
- Linda Xiaoyan Li, "Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression", Cell Death & Disease, 9(3), pp.326~ (2018), Springer Science and Business Media LLC[DOI]
- Linda Xiaoyan Li, "Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease", Journal of Clinical Investigation, 127(7), pp.2751~2764 (2017), American Society for Clinical Investigation[DOI]
- Haemin Kim, "S100A4 released from highly bone-metastatic breast cancer cells plays a critical role in osteolysis", Bone Research, 7(1), pp.30~ (2019), Springer Science and Business Media LLC[DOI]
- Keun Ha Park, "Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 Expression", 대한골대사학회지, 27(1), pp.53~63 (2020), 대한골대사학회
- Min Kyung Kim, "Salt-inducible kinase 1 regulates bone anabolism via the CRTC1–CREB–Id1 axis", Cell Death & Disease, 10(11), pp.826~ (2019), Springer Science and Business Media LLC[DOI]
- Min-Kyoung Song, "Gα12 regulates osteoclastogenesis by modulating NFATc1 expression", Journal of Cellular and Molecular Medicine, 22, pp.849~860 (2018), Wiley[DOI]
- Hiroshi Takayanagi, "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts", Developmental Cell, 3(6), pp.889~901 (2002), Elsevier BV[DOI]
- Agamemnon E. Grigoriadis, "c-Fos: a Key Regulator of Osteoclast-Macrophage Lineage Determination and Bone Remodeling", Science, 266(5184), pp.443~448 (1994), American Association for the Advancement of Science (AAAS)[DOI]
- Shuman Gao, "The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling", Journal of Biological Chemistry, 292(30), pp.12702~12712 (2017), Elsevier BV[DOI]
- Bongjun Kim, "A CTGF‐RUNX2‐RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone", Journal of Bone and Mineral Research, 35(1), pp.155~166 (2020), Wiley[DOI]
- Ezra Blumenthal, "Covalent Modifications of RUNX Proteins: Structure Affects Function", Advances in Experimental Medicine and Biology, 962, pp.33~44 (2017), Springer Singapore[DOI]
- Gang Huang, "The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS", AML-associated RUNX1, Blood, pp.2011, 118(25)[DOI]
- C P Koh, "RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes", Leukemia, 27(9), pp.1793~1802 (2013), Springer Science and Business Media LLC[DOI]
- J Herglotz, "Histone arginine methylation keeps RUNX1 target genes in an intermediate state", Oncogene, 32(20), pp.2565~2575 (2013), Springer Science and Business Media LLC[DOI]
- Soumen Chakraborty, "SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo", Oncogene, 22(34), pp.5229~5237 (2003), Springer Science and Business Media LLC[DOI]
- Di Yang, "Histone Demethylase Jmjd3 Regulates Osteoblast Differentiation via Transcription Factors Runx2 and Osterix", Journal of Biological Chemistry, 288(47), pp.33530~33541 (2013), Elsevier BV[DOI]
- Young-Yun Kong, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", Nature, 397(6717), pp.315~323 (1999), Springer Science and Business Media LLC[DOI]
- M. M. Tondravi, "Osteopetrosis in mice lacking haematopoietic transcription factor PU.1", Nature, 386(6620), pp.81~84 (1997), Springer Science and Business Media LLC[DOI]
- D.L Lacey, "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation", Cell, 93(2), pp.165~176 (1998), Elsevier BV[DOI]
- Peter F. Coccia, "Successful Bone-Marrow Transplantation for Infantile Malignant Osteopetrosis", New England Journal of Medicine, 302(13), pp.701~708 (1980), Massachusetts Medical Society[DOI]
- Michael Sorell, "Marrow transplantation for juvenile osteopetrosis", The American Journal of Medicine, 70(6), pp.1280~1287 (1981), Elsevier BV[DOI]
- Paul J. Orchard, "Hematopoietic stem cell transplantation for infantile osteopetrosis", Blood, 126(2), pp.270~276 (2015), American Society of Hematology[DOI]